Evidence map›Paper›PMID 32842985›Full record

ReviewBMC psychiatry2020

Effects of ∆

Ana Maria Raymundi, Thiago R da Silva, Jeferson M B Sohn, Leandro J Bertoglio, Cristina A Stern

Open access · goldAbstract readReview
In one paragraph

Review in BMC psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Real-Time Optical Control of CB1 Receptor SignalingJournal of the American Chemical Society · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. "Biomedicines · 2022
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ana Maria RaymundiDepartment of Pharmacology, Federal University of Parana, Curitiba, PR, Brazil.
Thiago R da SilvaDepartment of Pharmacology, Federal University of Parana, Curitiba, PR, Brazil.
Jeferson M B SohnDepartment of Pharmacology, Federal University of Parana, Curitiba, PR, Brazil.
Leandro J BertoglioDepartment of Pharmacology, Federal University of Santa Catarina, Florianopolis, SC, Brazil.
Cristina A SternDepartment of Pharmacology, Federal University of Parana, Curitiba, PR, Brazil. cristinastern.cs@gmail.com.ORCID 0000-0002-1736-5503
Universidade Federal do Paraná · BRUniversidade Federal de Santa Catarina · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 409615/2016-1Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação Araucária 006/2017
6 · The paper itself

Abstract

backgroundPosttraumatic stress disorder (PTSD) may stem from the formation of aberrant and enduring aversive memories. Some PTSD patients have recreationally used Cannabis, probably aiming at relieving their symptomatology. However, it is still largely unknown whether and how Cannabis or its psychotomimetic compound Δ

methodsMedline, PubMed, Cochrane Library, and Central Register for Controlled Trials databases were searched to identify peer-reviewed published studies and randomized controlled trials in humans published in English between 1974 and July 2020, including those using only THC and THC combined with cannabidiol (CBD). The effect size of the experimental intervention under investigation was calculated.

resultsAt low doses, THC can enhance the extinction rate and reduce anxiety responses. Both effects involve the activation of cannabinoid type-1 receptors in discrete components of the corticolimbic circuitry, which could couterbalance the low "endocannabinoid tonus" reported in PTSD patients. The advantage of associating CBD with THC to attenuate anxiety while minimizing the potential psychotic or anxiogenic effect produced by high doses of THC has been reported. The effects of THC either alone or combined with CBD on aversive memory reconsolidation, however, are still unknown.

conclusionsCurrent evidence from healthy humans and PTSD patients supports the THC value to suppress anxiety and aversive memory expression without producing significant adverse effects if used in low doses or when associated with CBD. Future studies are guaranteed to address open questions related to their dose ratios, administration routes, pharmacokinetic interactions, sex-dependent differences, and prolonged efficacy.

Indexed as

CannabidiolDronabinolAffectAnxietyHumansMemoryCannabidiolDronabinolCannabidiolCannabisFear extinctionMemory reconsolidationTHC

Identifiers

PMID32842985
PMCPMC7448997
OpenAlexW3081431549

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.